Clinical Trial Update: Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan [Phase 3]

View source ↗

Summary

Long-term, open-label Phase 3 study of tofacitinib (CP-690,550) for rheumatoid arthritis conducted in Japan has completed and posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2015-05-12